← Browse by Condition
Medical Condition

head and neck squamous cell carcinoma hnscc

Total Trials
6
Recruiting Now
6
Trial Phases
Phase 1, Phase 2, Phase 2, Phase 1

ClinicalMetric tracks all active clinical trials for head and neck squamous cell carcinoma hnscc sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — head and neck squamous cell carcinoma hnscc Clinical Trials

How many clinical trials are currently recruiting for head and neck squamous cell carcinoma hnscc?
ClinicalMetric currently tracks 6 actively recruiting clinical trials for head and neck squamous cell carcinoma hnscc, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 6. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for head and neck squamous cell carcinoma hnscc?
head and neck squamous cell carcinoma hnscc research spans Phase 1 (2 trials), Phase 2 (3 trials). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a head and neck squamous cell carcinoma hnscc clinical trial?
Eligibility criteria for head and neck squamous cell carcinoma hnscc trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 1
2
Phase 2
3
Top Sponsors
A2 Biotherapeutics Inc. 1 trial
Wake Forest University Health Sciences 1 trial
Tanabe Pharma America, Inc. 1 trial
Sun Yat-sen University 1 trial
John O. Prior 1 trial

Recruiting Clinical Trials

NCT04981119
Recruiting
Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
Enrollment
200 pts
Location
United States
Sponsor
A2 Biotherapeutics Inc.
View Trial →
NCT06607406
Recruiting
Postoperative Radiotherapy for Intermediate- and High-risk Patients With HNSCC Greater Than 6 Weeks After Surgery
Enrollment
75 pts
Location
United States
Sponsor
Wake Forest University Health ...
View Trial →
NCT06943521 Phase 1, Phase 2
Recruiting
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
Enrollment
27 pts
Location
United States, Japan
Sponsor
Tanabe Pharma America, Inc.
View Trial →
NCT06673693 Phase 2
Recruiting
Tislelizumab Combined With SBRT for the Treatment of Head and Neck Squamous Cell Carcinoma
Enrollment
24 pts
Location
China
Sponsor
Sun Yat-sen University
View Trial →
NCT06794372 Phase 2
Recruiting
[68Ga]Ga-FAPI-46 in Staging of Head and Neck Carcinomas
Enrollment
20 pts
Location
Switzerland
Sponsor
John O. Prior
View Trial →
NCT07457281 Phase 1
Recruiting
GV20-0251 and Sintilimab for Neoadjuvant Treatment of Resectable Head and Neck Squamous Cell Carcinoma: A Single-Arm Study
Enrollment
9 pts
Location
China
Sponsor
West China Hospital
View Trial →

Related Conditions

ovarian cancer (2) solid tumor adult (1) colorectal cancer (1) non small cell lung cancer (1) pancreatic cancer (1) crc (1) nsclc (1) pancreas cancer (1) mesothelioma (1) ovarian neoplasms (1) ovarian carcinoma (1) mesothelioma malignant (1)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology